Why it matters: The court's decision to side with Arbutus Biopharma means Arbutus could potentially sue Moderna for patent infringement and demand royalties from Moderna's COVID-19 vaccine, which is expected to generate up to $18 billion of revenue this year.
Get market news worthy of your time with Axios Markets. Subscribe for free.
Details: The patent cases have been ongoing since early 2018 and involve Arbutus' small lipid particles and other related mRNA drug technology.
In one of today's patent decisions, the court acknowledged how Shaun Ryan, Moderna's deputy general counsel, said there is "substantial risk that Arbutus may bring an infringement action relating to Moderna's COVID-19 vaccine."